We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 30. | 장 마감 후 (AMC) | $1.22 | — | — | $1.13B | — | 예정 |
| FY2026 Q1 | 2025. 03. 30. | 시각 미정 | — | $0.82 | — | — | $1.04B | 보고됨 |
| FY2025 Q3 | 2024. 09. 29. | 시각 미정 | — | $-8.86 | — | — | $3.27B |
Consensus PT $143.63 · 19 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 05. | Citigroup | — | 의견 유지 | Sell → Sell | — | Citigroup: Sell |
| 2026. 05. 02. | Canaccord Genuity | — | 의견 유지 | Hold → Hold | — | Canaccord Genuity: Hold |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-13.28 | — | — | $2.19B | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 73,717 | $9.09B | 0.01% | — | 신규 편입 |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 54,317 | $7.12B | 0.01% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Stored first · Google News · Yahoo Finance (English)
Is It Too Late To Reassess Illumina (ILMN) After A 98% One Year Surge? - simplywall.st
Is It Too Late To Reassess Illumina (ILMN) After A 98% One Year Surge? simplywall.st
Illumina Oncology Launches Put Product Depth Against Rapid Share Price Gains - Yahoo Finance Singapore
Illumina Oncology Launches Put Product Depth Against Rapid Share Price Gains Yahoo Finance Singapore
Illumina Ducks DNA Sequence Rival's Antitrust Suit, For Now - Law360
Illumina Ducks DNA Sequence Rival's Antitrust Suit, For Now Law360
Illumina Announces MRD Kit Ahead of ASCO Meeting - Genetic Engineering and Biotechnology News
Illumina Announces MRD Kit Ahead of ASCO Meeting Genetic Engineering and Biotechnology News
Illumina and SPT Labtech launch fireflyGO for automated oncology research - Yahoo Tech
Illumina and SPT Labtech launch fireflyGO for automated oncology research Yahoo Tech